230
http://www.aard.or.kr설문조사를 통한 국내 유전성 혈관부종 진료 현황 및 국내 사례 문헌고찰
이서영
1, 강혜련
1, 정재우
2, 장광천
3, 이수영
4, 안영민
5, 민경업
1; 대한천식알레르기학회 아나필락시스 워크그룹*
1서울대학교 의과대학 내과학교실, 2중앙대학교 의과대학 내과학교실, 3국민건강보험 일산병원 소아청소년과, 4아주대학교 의과대학 소아청소년과학교실,
5을지대학교 의과대학 소아청소년과학교실
Clinical experience in managing patients with hereditary angioedema in Korea: questionnaire survey and a literature review
Suh-Young Lee
1, Hye-Ryun Kang
1, Jae Woo Jung
2, Gwang Cheon Jang
3, Soo Young Lee
4, Youngmin Ahn
5, Kyung-Up Min
1; Korean Academy of Asthma, Allergy and Clinical Immunology Anaphylaxis Work Group*
1Department of Internal Medicine, Seoul National University College of Medicine, Seoul; 2Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul; 3Department of Pediatrics, National Health Insurance Corporation Ilsan Hospital, Goyang; 4Department of Pediatrics and Adolescent Medicine, Ajou University School of Medicine, Suwon; 5Department of Pediatrics, Eulji University School of Medicine, Daejeon, Korea
Allergy Asthma Respir Dis 2014;2(4):277-284 http://dx.doi.org/10.4168/aard.2014.2.4.277
이 논문의 Table 3에서 각주(footnote)에 대한 설명 표기가 잘못되어 아래와 같이 이를 정정합니다.
·Table 3 각주(footnote) 설명 표기 수정 사항
*Only Cinryze is approved for maintenance treatment by Food and Drug Administration. †Bradykinin B2 receptor antagonist. ‡Kallikrein inhibitor.
pISSN: 2288-0402 eISSN: 2288-0410
ERRATUM: Correction of explanation for footnote in Table 3
Allergy Asthma Respir Dis 4(3):230-230, May 2016 http://dx.doi.org/10.4168/aard.2016.4.3.230
© 2016 The Korean Academy of Pediatric Allergy and Respiratory Disease The Korean Academy of Asthma, Allergy and Clinical Immunology This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).
